CDKN2A and neoplasm: Of 21 tumor samples with expression data for p16IN4a and BRG1 18 (86%) had lost at least one of these proteins, predominantly p16INK4a, and among these were 10 tumors (48%) negative for both, while 3 samples 14% had retained expression of both p16INK4a and BRG1.